Tvardi Therapeutics, Inc.
TVRD
$3.02
$0.020.67%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
4/2/2026
-
Globe Newswire
4/2/2026
-
TipRanks Financial Blog
4/1/2026
-
Ticker Report
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Given Average Recommendation of "Moderate Buy" by Brokerages
4/1/2026
-
Ticker Report
3/31/2026
-
The Fly
3/31/2026
-
SeekingAlpha.com: All News
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
3/31/2026
-
Globe Newswire
3/6/2026
-
TipRanks Financial Blog
3/2/2026
-
Ticker Report
2/23/2026
-
TipRanks Financial Blog
2/12/2026
-
Globe Newswire
2/5/2026
-
Ticker Report
2/4/2026
-
TipRanks Financial Blog
2/4/2026
-
The Fly
1/29/2026
-
TipRanks Financial Blog
1/29/2026
-
Simply Wall St
1/8/2026
-
GuruFocus
1/8/2026
-
Globe Newswire
1/8/2026
-
GuruFocus
1/8/2026
-
The Fly
1/8/2026
-
GuruFocus
1/8/2026
-
Globe Newswire
12/31/2025
-
Ticker Report
12/24/2025
-
Globe Newswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Tuesday, March 31, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of May 25 and 29 (est)
Price History
Beta
--
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
713 489 8654
Address
3 Sugar Creek Center Boulevard
Sugar Land, TX 77478
Sugar Land, TX 77478
Country
Year Founded
Business Description
Sector
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of...
more